Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COCH Stock Forecast 2026-2027
$0.69
Current Price
$19.88M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to COCH Price Targets
+918.5%
To High Target of $7.00
+918.5%
To Median Target of $7.00
+918.5%
To Low Target of $7.00
COCH Price Momentum
+1.5%
1 Week Change
-1.4%
1 Month Change
-51.1%
1 Year Change
+4.5%
Year-to-Date Change
-64.0%
From 52W High of $1.91
+7.4%
From 52W Low of $0.64
📊 TOP ANALYST CALLS
Did COCH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Envoy Medical is one of their latest high-conviction picks.
Latest COCH Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, COCH has a bullish consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.69, the median forecast implies a 918.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCH Analyst Ratings
1
Buy
0
Hold
0
Sell
COCH Price Target Range
Low
$7.00
Average
$7.00
High
$7.00
Current: $0.69
Latest COCH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.50 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.25 |
| Dec 6, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.00 |
| Oct 14, 2024 | Brookline Capital | Tyler Bussian | Buy | Initiates | $9.00 |
| Sep 3, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.75 |
| Jun 24, 2024 | Ascendiant Capital | Edward Woo | Buy | Initiates | $8.50 |
| Apr 3, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
| Dec 21, 2023 | Northland Capital Markets | Carl Byrnes | Outperform | Initiates | $N/A |
| Nov 28, 2023 | Lake Street | Frank Takkinen | Buy | Initiates | $3.00 |
Envoy Medical, Inc. (COCH) Competitors
The following stocks are similar to Envoy Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Envoy Medical, Inc. (COCH) Financial Data
Envoy Medical, Inc. has a market capitalization of $19.88M with a P/E ratio of -0.5x. The company generates $208,000 in trailing twelve-month revenue with a -229.8% profit margin.
Revenue growth is -25.0% quarter-over-quarter, while maintaining an operating margin of -13,590.5% and return on equity of +148.5%.
Valuation Metrics
Market Cap
$19.88M
Enterprise Value
$16.71M
P/E Ratio
-0.5x
PEG Ratio
0.1x
Price/Sales
95.7x
Growth & Margins
Revenue Growth (YoY)
-25.0%
Gross Margin
-383.3%
Operating Margin
-13,590.5%
Net Margin
-229.8%
EPS Growth
-25.0%
Financial Health
Cash/Price Ratio
+18.0%
Current Ratio
0.6x
Debt/Equity
-0.1x
ROE
+148.5%
ROA
-145.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Envoy Medical, Inc. (COCH) Business Model
About Envoy Medical, Inc.
What They Do
Develops innovative medical devices for hearing healthcare.
Business Model
Envoy Medical, Inc. generates revenue by designing and developing advanced medical devices that provide solutions for individuals with hearing loss. The company focuses on leveraging cutting-edge technology to enhance auditory performance, thus catering to a growing demographic in need of sophisticated hearing aids.
Additional Information
The company operates within the broader medical device industry, impacting sectors like audiology and otolaryngology. Envoy Medical is dedicated to research and development, aiming to improve patient outcomes and quality of life for those with hearing impairments. Its innovative contributions are crucial for both patients and healthcare providers, integrating seamlessly into medical practices worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
42
CEO
Mr. Brent T. Lucas Esq.
Country
United States
IPO Year
2023
Website
www.envoymedical.comEnvoy Medical, Inc. (COCH) Latest News & Analysis
Latest News
Quick Summary
Envoy Medical Inc. (NASDAQ: COCH) reported it has reached the midway point in enrollment for its pivotal clinical study of the Acclaim® cochlear implant, despite year-end challenges.
Why It Matters
Accelerating enrollment in Envoy Medical's pivotal study signals confidence in product demand and potential regulatory approval, positively influencing stock performance and investor sentiment.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical Inc. (NASDAQ: COCH) has completed the first activations in the pivotal clinical study for its Acclaim® cochlear implant, advancing its hearing health solutions.
Why It Matters
Positive clinical milestones and differentiation in design enhance Envoy Medical's competitive position, potentially boosting investor confidence and stock value.
Source: Newsfile Corp
Market Sentiment:
Neutral
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
1 month ago
Quick Summary
Envoy Medical Inc. (NASDAQ: COCH) will host a fireside chat on December 11, 2025, at 4:30 P.M. ET, discussing its fully implanted hearing solutions.
Why It Matters
The fireside chat may reveal strategic insights or updates on Envoy Medical's innovations, potentially influencing stock performance and investor sentiment in the hearing health sector.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical, Inc. (COCH) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.
Why It Matters
Envoy Medical's upgrade to a Zacks Rank #2 signals strong earnings potential, likely boosting investor confidence and driving stock demand upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Envoy Medical Inc. (NASDAQ: COCH) has secured its 40th active U.S. patent, enhancing its intellectual property portfolio, which also includes 45 foreign patents, focusing on fully implanted hearing devices.
Why It Matters
Envoy Medical's new patent enhances its competitive edge and intellectual property value, potentially leading to increased market share and revenue growth, which can positively impact stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical (NASDAQ: COCH) has been granted U.S. Patent No. 12,465,754, enhancing its intellectual property portfolio and solidifying its position in cochlear implant innovation.
Why It Matters
The new patent strengthens Envoy Medical's competitive edge in cochlear implants, potentially boosting market share and driving future revenue growth, which is favorable for stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About COCH Stock
What is Envoy Medical, Inc.'s (COCH) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Envoy Medical, Inc. (COCH) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is COCH stock a good investment in 2026?
According to current analyst ratings, COCH has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COCH stock?
Wall Street analysts predict COCH stock could reach $7.00 in the next 12 months. This represents a 918.5% increase from the current price of $0.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Envoy Medical, Inc.'s business model?
Envoy Medical, Inc. generates revenue by designing and developing advanced medical devices that provide solutions for individuals with hearing loss. The company focuses on leveraging cutting-edge technology to enhance auditory performance, thus catering to a growing demographic in need of sophisticated hearing aids.
What is the highest forecasted price for COCH Envoy Medical, Inc.?
The highest price target for COCH is $7.00 from at , which represents a 918.5% increase from the current price of $0.69.
What is the lowest forecasted price for COCH Envoy Medical, Inc.?
The lowest price target for COCH is $7.00 from at , which represents a 918.5% increase from the current price of $0.69.
What is the overall COCH consensus from analysts for Envoy Medical, Inc.?
The overall analyst consensus for COCH is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are COCH stock price projections?
Stock price projections, including those for Envoy Medical, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 1:03 PM UTC